Comerica Securities’s Sanofi SNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
$494K Sell
9,201
-4,317
-32% -$230K 0.04% 274
2023
Q2
$729K Sell
13,518
-290
-2% -$15.6K 0.05% 260
2023
Q1
$751K Buy
13,808
+6,069
+78% +$295K 0.05% 254
2022
Q4
$375K Buy
+7,739
New +$340K 0.03% 346
2022
Q3
Sell
-7,493
Closed -$375K 468
2022
Q2
$375K Buy
7,493
+2,941
+65% +$156K 0.03% 341
2022
Q1
$234K Buy
+4,552
New +$235K 0.02% 445
2018
Q3
Sell
-7,384
Closed -$295K 437
2018
Q2
$295K Buy
7,384
+74
+1% +$2.91K 0.04% 342
2018
Q1
$293K Sell
7,310
-895
-11% -$37.2K 0.04% 337
2017
Q4
$353K Sell
8,205
-2,142
-21% -$98.8K 0.04% 309
2017
Q3
$515K Sell
10,347
-3,811
-27% -$184K 0.07% 250
2017
Q2
$678K Sell
14,158
-591
-4% -$28.2K 0.1% 216
2017
Q1
$667K Buy
14,749
+2,450
+20% +$104K 0.11% 220
2016
Q4
$497K Sell
12,299
-311
-2% -$12.3K 0.12% 192
2016
Q3
$482K Buy
12,610
+4,810
+62% +$193K 0.09% 219
2016
Q2
$326K Buy
+7,800
New +$320K 0.07% 258

Other funds holding SNY

Comerica Securities's SNY Position: Q3 2023 in Review

Comerica Securities reduced its Sanofi (SNY) stake by 32% in Q3 2023, selling an estimated $230K and leaving 9,201 shares worth $494K. The position accounts for 0.04% of the portfolio, ranked #274.

Comerica Securities first reported a position in SNY in Q2 2016 and has held it in 15 quarters since. The position peaked at $751K in Q1 2023. 696 funds tracked by Wall St. Rank hold SNY as of Q3 2023.

  • Comerica Securities held 9,201 shares of Sanofi worth $494K as of Q3 2023.
  • Comerica Securities sold 4,317 Sanofi shares in Q3 2023, an estimated $230K.
  • Sanofi made up 0.04% of Comerica Securities's portfolio in Q3 2023, its #274 holding.
  • Comerica Securities first reported a position in Sanofi in Q2 2016 and has held it in 15 quarters since.
  • Comerica Securities's Sanofi position peaked at $751K in Q1 2023.
  • 696 funds tracked by Wall St. Rank held Sanofi as of Q3 2023.

Based on Comerica Securities's 13F filing for Q3 2023, filed 26 Oct 2023.